🇺🇸 FDA
Pipeline program

LX3305 low dose

Protocol LX3305.1-201-RA

Phase 2 small_molecule completed

Quick answer

LX3305 low dose for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LEXICON PHARMACEUTICALS, INC.
Indication
Rheumatoid Arthritis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials